Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

Nektar Cuts 70% of Workforce on Heels of BMS-Partnered Collapse

Nektar Cuts 70% of Workforce on Heels of BMS-Partnered Collapse

On Monday, Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce.

Study Reveals Pharmaceutical Companies’ Reputations Improved Due to COVID-19

Study Reveals Pharmaceutical Companies’ Reputations Improved Due to COVID-19

The public image of drugmakers has improved significantly during the pandemic, according to the latest annual survey by PatientView, a UK-based research and consulting firm. ...

Pfizer Recalls Blood Pressure and Heart Failure Drug Accupril Due to Nitrosamine Content

Pfizer Recalls Blood Pressure and Heart Failure Drug Accupril Due to Nitrosamine Content

Pfizer has recalled five lots of Accupril (Quinapril HCl), its blood pressure adjunctive therapy for heart failure, due to the presence of unacceptable levels of a nitrosamine. ...

EMA Has More Questions About Valneva’s Inactive COVID-19 Vaccine

EMA Has More Questions About Valneva’s Inactive COVID-19 Vaccine

Valneva said the European Medicines Agency (EMA) has asked for more data on the company’s COVID-19 vaccine candidate, VLA2001, which the agency is reviewing for a possible marketing authorization...

FDA Grants Priority Review to AstraZeneca’s Adjunct HCC Drug

FDA Grants Priority Review to AstraZeneca’s Adjunct HCC Drug

The FDA has granted a Priority Review designation to AstraZeneca’s Biologics License Application (BLA) for tremelimumab as adjunct therapy to the company’s blockbuster drug Imfinzi (durvalumab...

Leo, Janssen, Teva, Lundbeck, Otsuka Europe, Daiichi-Sankyo, and Roche named in advertisements for breaches of the ABPI Code

Leo, Janssen, Teva, Lundbeck, Otsuka Europe, Daiichi-Sankyo, and Roche named in advertisements for breaches of the ABPI Code

Seven companies have been named in advertisements for bringing discredit upon, and reducing confidence in, the pharmaceutical industry. In addition, Janssen was publicly reprimanded.

Astellas Drops Duchenne Muscular Dystrophy Gene Therapies and Other Studies

Astellas Drops Duchenne Muscular Dystrophy Gene Therapies and Other Studies

Astellas Pharma said it will end three gene therapy programs for the treatment of patients with Duchenne muscular dystrophy (DMD) based on disappointing preclinical data, along with several other p...

Vitamin-D, Omega-3, exercise can reduce cancer risk by 61%: StudyVitamin-D, Omega-3, exercise can reduce cancer risk by 61%: Study

Vitamin-D, Omega-3, exercise can reduce cancer risk by 61%: StudyVitamin-D, Omega-3, exercise can reduce cancer risk by 61%: Study

A combination of high-dose Vitamin D, Omega-3s, and simple home strength exercises can help reduce cancer risk in healthy adults aged 70 or older by 61 per cent, claims a study. ...

Catalent snaps up NJ cell therapy plant for $44.5M days after revealing big biologics expansion

Catalent snaps up NJ cell therapy plant for $44.5M days after revealing big biologics expansion

Days after throwing down $350 million to beef up biologics manufacturing in Indiana, high-flying CDMO Catalent is buying a cell therapy plant on the East Coast. ...

FDA grants fast track designation to CMG901 for gastrointestinal cancers

FDA grants fast track designation to CMG901 for gastrointestinal cancers

The FDA granted fast track designation to CMG901 for treatment of certain patients with gastrointestinal cancers.

Landmark DNA study finds 58 new mutations that cause cancer

Landmark DNA study finds 58 new mutations that cause cancer

A massive study has analyzed the genomes of cancer cells from more than 12,000 patients, identifying 58 new mutational signatures that offer clues to novel causes of cancer. ...

Study Reveals Inappropriate Antibiotic Prescription Practices

Study Reveals Inappropriate Antibiotic Prescription Practices

Almost three-quarters of antibiotic prescriptions to patients aged 65 years or older and two-thirds to Black patients are inappropriate, according to a U.S. study of more than 7 billion visits to d...

45 46 47 484950 51 52 53